Stay updated on EMpagliflozin Effects on Cardiac Function in AMI - Clinical Trial

Sign up to get notified when there's something new on the EMpagliflozin Effects on Cardiac Function in AMI - Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the EMpagliflozin Effects on Cardiac Function in AMI - Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the impact of Empagliflozin on biomarkers of heart failure in patients with acute myocardial infarction, particularly focusing on patients with and without type 2 diabetes mellitus.
    Difference
    0.1%
    Check dated 2024-06-06T14:29:02.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to a detailed description of eligibility criteria, explaining that researchers seek individuals who meet specific health conditions or prior treatments. The new text also provides an example of inclusion criteria for myocardial infarction with significant myocardial necrosis.
    Difference
    18%
    Check dated 2024-05-22T21:09:01.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:26:15.000Z thumbnail image

Stay in the know with updates to EMpagliflozin Effects on Cardiac Function in AMI - Clinical Trial

Enter your email address, and we'll notify you when there's something new on the EMpagliflozin Effects on Cardiac Function in AMI - Clinical Trial page.